AARD — Aardvark Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $277.94m
- $136.12m
- 23
- 31
- 63
- 32
Annual cashflow statement for Aardvark Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -13.6 | -7.21 | -20.6 |
| Depreciation | |||
| Non-Cash Items | 4.33 | 1.47 | 0.912 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -1.31 | -0.081 | 1.57 |
| Change in Prepaid Expenses | |||
| Change in Accounts Payable | |||
| Change in Accrued Expenses | |||
| Cash from Operating Activities | -10.5 | -5.82 | -18.1 |
| Capital Expenditures | — | — | -0.109 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -1 | 0 | -11.9 |
| Purchase of Investments | |||
| Other Investing Cash Flow | |||
| Cash from Investing Activities | -1 | 0 | -12 |
| Financing Cash Flow Items | — | — | -3.34 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Cash from Financing Activities | 0.225 | 0 | 82 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -11.3 | -5.82 | 51.9 |